PATENT CLAIM ANALYSIS

Application Number: 16079868
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
Aberrantly expressed piRNAs, genetically associated piRNAs and their relationship with cancer risk and severity are provided. Compositions and methods of using piRNA for treating cancer are provided. Methods of diagnosing subjects and determining the efficacy of active agents for treating cancer are also provided. Methods of correlating variant piRNA to cancer are also disclosed.

Claim (Index 24):
The method of  claim 23 , wherein\n (i) wildtype piR_016975 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_016975 is underexpressed in the cancer relative to normal tissue, (ii) wildtype piR_019169 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_019169 is underexpressed in the cancer relative to normal tissue, (iii) wildtype piR_018292 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_018292 is underexpressed in the cancer relative to normal tissue, (iv) wildtype piR_017178 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_017178 is underexpressed in the cancer relative to normal tissue, (v) wildtype piR_019368 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_019368 is underexpressed in the cancer relative to normal tissue, (vi) wildtype piR_019911 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_019911 is underexpressed in the cancer relative to normal tissue, (vii) wildtype piR_000560 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_000560 is underexpressed in the cancer relative to normal tissue, (viii) wildtype piR_001207 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_001207 is underexpressed in the cancer relative to normal tissue, (ix) wildtype piR_012753 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_012753 is underexpressed in the cancer relative to normal tissue, (x) wildtype piR_003728 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_003728 is underexpressed in the cancer relative to normal tissue, (xi) wildtype piR_001078 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_001078 is underexpressed in the cancer relative to normal tissue, (xii) wildtype piR_012925 or a close variant thereof with the same or similar activity to wildtype, or a stimulator of expression thereof is administered and piR_012925 is underexpressed in the cancer relative to normal tissue, or (xiii) combination thereof

Metadata:
- Claim Count in Document: 6.0
- Percentile: 96.0
- Lexical Diversity: 1.63889
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13470233', '15313555', '14112296', '14020811', '15422725']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7577780842597056
- 35 USC 102 Novelty (BERT): 0.5193605011967461
- Combined Prediction Score: 0.7339363259534096
- Mean Citation Score: 233.341736
- Max Citation Score: 247.30536
- Similarity Product: 134.20020551443577

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test